Published in Bull Math Biol on December 01, 2007
Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia. PLoS One (2011) 1.32
Mathematical modeling as a tool for planning anticancer therapy. Eur J Pharmacol (2009) 0.92
Merging concepts - coupling an agent-based model of hematopoietic stem cells with an ODE model of granulopoiesis. BMC Syst Biol (2013) 0.83
Quantitative modeling of chronic myeloid leukemia: insights from radiobiology. Blood (2012) 0.81
A multicellular basis for the origination of blast crisis in chronic myeloid leukemia. Cancer Res (2011) 0.79
Computer modeling describes gravity-related adaptation in cell cultures. PLoS One (2009) 0.77
A Review of Mathematical Models for Leukemia and Lymphoma. Drug Discov Today Dis Models (2014) 0.75
Optimization and Control of Agent-Based Models in Biology: A Perspective. Bull Math Biol (2016) 0.75
Dynamical models of mutated chronic myelogenous leukemia cells for a post-imatinib treatment scenario: Response to dasatinib or nilotinib therapy. PLoS One (2017) 0.75
Long-term treatment effects in chronic myeloid leukemia. J Math Biol (2017) 0.75
Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med (2003) 3.60
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother (2002) 2.65
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res (2011) 2.44
Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med (2005) 2.12
Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med (2007) 1.89
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest (2003) 1.70
Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci U S A (2009) 1.66
A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res (2002) 1.56
Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Proc Natl Acad Sci U S A (2003) 1.56
Role of symmetric and asymmetric division of stem cells in developing drug resistance. Proc Natl Acad Sci U S A (2010) 1.53
Marked differences in human melanoma antigen-specific T cell responsiveness after vaccination using a functional microarray. PLoS Med (2005) 1.42
Diversity and recognition efficiency of T cell responses to cancer. PLoS Med (2004) 1.36
Development and dynamics of robust T-cell responses to CML under imatinib treatment. Blood (2008) 1.34
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31
Rational design of combination enzyme therapy for celiac sprue. Chem Biol (2006) 1.28
Dynamics and potential impact of the immune response to chronic myelogenous leukemia. PLoS Comput Biol (2008) 1.26
Engineered vaginal lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N. Antimicrob Agents Chemother (2006) 1.25
Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer (2003) 1.24
Memory T cells have gene expression patterns intermediate between naive and effector. Proc Natl Acad Sci U S A (2005) 1.18
Multiscale registration of planning CT and daily cone beam CT images for adaptive radiation therapy. Med Phys (2009) 1.15
The dynamics of drug resistance: a mathematical perspective. Drug Resist Updat (2012) 1.12
Hybrid multiscale landmark and deformable image registration. Math Biosci Eng (2007) 1.10
Multiscale deformable registration of noisy medical images. Math Biosci Eng (2008) 1.08
Regulation of chemerin bioactivity by plasma carboxypeptidase N, carboxypeptidase B (activated thrombin-activable fibrinolysis inhibitor), and platelets. J Biol Chem (2008) 1.06
A Chinese rhesus macaque (Macaca mulatta) model for vaginal Lactobacillus colonization and live microbicide development. J Med Primatol (2009) 1.05
An Interactive Java Statistical Image Segmentation System: GemIdent. J Stat Softw (2009) 1.05
Engineering of a human vaginal Lactobacillus strain for surface expression of two-domain CD4 molecules. Appl Environ Microbiol (2008) 1.04
Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010". J Transl Med (2011) 1.02
A PDE model for imatinib-treated chronic myelogenous leukemia. Bull Math Biol (2008) 1.02
An elementary approach to modeling drug resistance in cancer. Math Biosci Eng (2010) 0.99
Modeling regulation mechanisms in the immune system. J Theor Biol (2006) 0.95
Modeling local interactions during the motion of cyanobacteria. J Theor Biol (2012) 0.94
Quantitative, architectural analysis of immune cell subsets in tumor-draining lymph nodes from breast cancer patients and healthy lymph nodes. PLoS One (2010) 0.93
A self-directed method for cell-type identification and separation of gene expression microarrays. PLoS Comput Biol (2013) 0.93
Agent-based modeling of the context dependency in T cell recognition. J Theor Biol (2005) 0.92
Modeling and simulation of the immune system as a self-regulating network. Methods Enzymol (2009) 0.92
Microarray analysis reveals differences in gene expression of circulating CD8(+) T cells in melanoma patients and healthy donors. Cancer Res (2004) 0.91
Multiscale image registration. Math Biosci Eng (2006) 0.90
Altered local and systemic immune profiles underlie lymph node metastasis in breast cancer patients. Int J Cancer (2012) 0.89
Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients. J Transl Med (2011) 0.88
Rapid assessment of recognition efficiency and functional capacity of antigen-specific T-cell responses. J Immunother (2005) 0.88
PRC2/EED-EZH2 complex is up-regulated in breast cancer lymph node metastasis compared to primary tumor and correlates with tumor proliferation in situ. PLoS One (2012) 0.88
A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma. Clin Cancer Res (2003) 0.88
Emergent group dynamics governed by regulatory cells produce a robust primary T cell response. Bull Math Biol (2009) 0.87
The role of cell density and intratumoral heterogeneity in multidrug resistance. Cancer Res (2013) 0.86
Spatial organization of dendritic cells within tumor draining lymph nodes impacts clinical outcome in breast cancer patients. J Transl Med (2013) 0.85
A mathematical model of the enhancement of tumor vaccine efficacy by immunotherapy. Bull Math Biol (2012) 0.84
Modeling selective local interactions with memory. Physica D (2013) 0.82
Modeling protective anti-tumor immunity via preventative cancer vaccines using a hybrid agent-based and delay differential equation approach. PLoS Comput Biol (2012) 0.82
Quantitative and spatial image analysis of tumor and draining lymph nodes using immunohistochemistry and high-resolution multispectral imaging to predict metastasis. Methods Mol Biol (2014) 0.82
Registration-based morphing of active contours for segmentation of ct scans. Math Biosci Eng (2005) 0.81
Melanoma NOS1 expression promotes dysfunctional IFN signaling. J Clin Invest (2014) 0.81
Cytotoxic T lymphocyte responses against melanocytes and melanoma. J Transl Med (2011) 0.81
Post-transplantation dynamics of the immune response to chronic myelogenous leukemia. J Theor Biol (2005) 0.80
In vivo evaluation of safety and toxicity of a Lactobacillus jensenii producing modified cyanovirin-N in a rhesus macaque vaginal challenge model. PLoS One (2013) 0.79
T cell state transition produces an emergent change detector. J Theor Biol (2011) 0.78
Identification of Epstein-Barr virus-specific CD8+ T lymphocytes in the circulation of pediatric transplant recipients. Transplantation (2002) 0.78
Functional switching and stability of regulatory T cells. Bull Math Biol (2013) 0.77
The impact of cell density and mutations in a model of multidrug resistance in solid tumors. Bull Math Biol (2014) 0.77
Applying mathematical tools to accelerate vaccine development: modeling Shigella immune dynamics. PLoS One (2013) 0.77
B7-h1 and a mathematical model for cytotoxic T cell and tumor cell interaction. Bull Math Biol (2011) 0.77
Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus antigens in patients with Epstein-Barr virus-negative Hodgkin's disease. Oncol Res (2009) 0.76
Strategic treatment interruptions during imatinib treatment of chronic myelogenous leukemia. Bull Math Biol (2010) 0.76
Demonstration of vaginal colonization with GusA-expressing Lactobacillus jensenii following oral delivery in rhesus macaques. Res Microbiol (2011) 0.75
A theory of immunodominance and adaptive regulation. Bull Math Biol (2010) 0.75
Partial differential equations-based segmentation for radiotherapy treatment planning. Math Biosci Eng (2005) 0.75
Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients. Immunopharmacol Immunotoxicol (2014) 0.75
Comparison of three methods of pre-employment medical evaluations. Occup Med (Lond) (2007) 0.75
[Return to work with heart disease]. Harefuah (2007) 0.75
Corrigendum to:Agent-based modeling of the context dependency in T cell recognition. J Theor Biol (2012) 0.75